checkAd

     1107  0 Kommentare Hamilton Thorne Announces the Acquisition of Gynemed GmbH & Co. KG and Related Financing Transactions

    BEVERLY, MASSACHUSETTS and TORONTO, ONTARIO--(Marketwired - April 28, 2017) - Hamilton Thorne Ltd. (TSX VENTURE:HTL) ("Hamilton Thorne" or the "Company"), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets today announced that it has completed the acquisition of Gynemed GmbH & Co. KG ("Gynemed") for total consideration of Euro 13.9 million (approximately US$15.1 million) (the "Transaction").

    Gynemed, based in Lensahn, Germany is a leading manufacturer and distributor of consumables and equipment for the in vitro fertilization ("IVF") clinic and laboratory markets. The Transaction results in the significant expansion of Hamilton Thorne's product offerings and provides the Company with profitable operations in the well-established European ART market. For the year ended December 31, 2016, Gynemed had revenues of approximately Euro 8.8 million (approximately US$9.6 million), net income of approximately Euro 2.2 million (approximately US$2.4 million) and EBITDA of approximately Euro 2.6 million (approximately US$2.8 million).

    Key Benefits of the Transaction:

    • Addition of a profitable portfolio of premium products that are highly complementary to Hamilton Thorne's existing product and service offerings
    • Expected to be materially accretive to revenue and EBITDA
    • Diversifies and increases product offerings and recurring revenue
    • Opportunity to expand Gynemed product offerings into additional international markets and to increase European sales of existing Hamilton Thorne products
    • Financed through the expansion of an existing credit facility and an equity offering

    "We are excited to welcome our new partners from Gynemed to the Hamilton Thorne family. This transformative acquisition significantly enhances the size of our business and provides a new platform for continued growth of our business," said David Wolf, President and Chief Executive Officer of Hamilton Thorne. "Gynemed is a well-established and respected provider of premium clinical and laboratory consumables and equipment in the European ART market that importantly shares our total commitment to the highest standards in customer service and quality. I am particularly excited that all of Gynemed's current employees and leadership team will continue to operate and lead the growth of the existing Gynemed business and collaborate with our existing Hamilton Thorne team on several new avenues of growth for our combined operations. This acquisition enhances our presence in the very attractive European ART market, further diversifies our revenue base and increases our percentage of recurring revenues through the sale of consumable products, including Gynemed's IVF cell culture media solutions."

    Seite 1 von 5


    Verfasst von Marketwired
    Hamilton Thorne Announces the Acquisition of Gynemed GmbH & Co. KG and Related Financing Transactions BEVERLY, MASSACHUSETTS and TORONTO, ONTARIO--(Marketwired - April 28, 2017) - Hamilton Thorne Ltd. (TSX VENTURE:HTL) ("Hamilton Thorne" or the "Company"), a leading provider of precision instruments, consumables, software and services to the …